{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:58:04Z","timestamp":1785459484215,"version":"3.56.0"},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      Global oncology trials face increasing scrutiny over regional enrollment imbalances, as regulatory agencies such as the US Food and Drug Administration, European Medicines Agency, and Pharmaceuticals and Medical Devices Agency demand data reflective of population diversity. This push is grounded in evidence that genetic polymorphisms (eg,\n                      <jats:italic toggle=\"yes\">UGT1A1*<\/jats:italic>\n                      28,\n                      <jats:italic toggle=\"yes\">CYP2D6<\/jats:italic>\n                      ), human leukocyte antigen\u2013related toxicities, and biomarker prevalence (eg, epidermal growth factor receptor\n                      <jats:italic toggle=\"yes\"\/>\n                      mutations in approximately 15% of Western\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      approximately 50% of Asian patients with lung cancer) can significantly influence treatment outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We reviewed scientific literature, regulatory case studies, and methodological innovations addressing regional heterogeneity in oncology trials. Particular focus was given to statistical tools such as adaptive randomization for real-time enrollment balancing, Bayesian hierarchical models for data borrowing across regions, and Multi-Regional Clinical Trial designs for structured consistency assessments. Control arm variability because of regional differences in standard of care and drug access was also examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Recent regulatory setbacks, especially involving Asia-centric trials, underscore the consequences of insufficient regional planning. Emerging statistical approaches, including adaptive and Bayesian methods, show promise in managing heterogeneity while preserving trial integrity. Persistent challenges include disparities in trial infrastructure, molecular subtype distributions, and comorbidity patterns. Broader regional inclusion and integration of real-world evidence are increasingly critical to overcoming these limitations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Regional enrollment should be viewed not as a regulatory formality, but as a scientific and ethical priority. The future of global oncology trials hinges on proactive regional planning, innovative methodology, and cross-sector collaboration. Aligning global efficiency with local relevance can enhance scientific robustness, support regulatory alignment, and expand equitable access to novel cancer therapies worldwide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/go-25-00285","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:58:11Z","timestamp":1770238691000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Global Trials, Local Relevance: A Scientific and Regulatory Framework for Regional Enrollment in Cancer Drug Development"],"prefix":"10.1200","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4392-4505","authenticated-orcid":true,"given":"Denis","family":"Horgan","sequence":"first","affiliation":[{"name":"European Alliance for Personalised Medicine, Brussels, Belgium"},{"name":"Department of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Faculty of Engineering and Technology, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, India"},{"name":"International Cancer Patient Coalition, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6263-0313","authenticated-orcid":true,"given":"Zorana","family":"Maravic","sequence":"additional","affiliation":[{"name":"Digestive Cancers Europe, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Mastris","sequence":"additional","affiliation":[{"name":"Tackle Prostate Cancer, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7705-2170","authenticated-orcid":true,"given":"Hadi","family":"Mohamad Abu Rasheed","sequence":"additional","affiliation":[{"name":"Qatar Cancer Society, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0514-0152","authenticated-orcid":true,"given":"Carolina","family":"Reduzzi","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-335X","authenticated-orcid":true,"given":"Adda","family":"Bounedjar","sequence":"additional","affiliation":[{"name":"University of Blida 1, Faculty of Medicine, BP 270, Route de soumaa, Blida, Algeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Elghazaly","sequence":"additional","affiliation":[{"name":"Egyptian Cancer Society, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Mohar","sequence":"additional","affiliation":[{"name":"International Cancer Patient Coalition, Brussels, Belgium"},{"name":"SWOG, Instituto Nacional de Cancerologia (INCan), Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1141-7608","authenticated-orcid":true,"given":"Roberto","family":"Pestana","sequence":"additional","affiliation":[{"name":"International Cancer Patient Coalition, Brussels, Belgium"},{"name":"Hospital Israelita Albert Einstein, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1929-1843","authenticated-orcid":true,"given":"Jonathan A.","family":"Lal","sequence":"additional","affiliation":[{"name":"International Cancer Patient Coalition, Brussels, Belgium"},{"name":"Sam Higginbottom University of Agriculture, Technology And Sciences (SHUATS), Prayagraj, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3211-9957","authenticated-orcid":true,"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[{"name":"Department of Public Health, University Federico II of Naples, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Asgary","sequence":"additional","affiliation":[{"name":"International Cancer Patient Coalition, Brussels, Belgium"},{"name":"Department of Global Health, Milken Institute School of Public Health, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":true,"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[{"name":"International Cancer Patient Coalition, Brussels, Belgium"},{"name":"Sarah Cannon Research Institute, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104086"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-023-02003-6"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1301"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15242"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-020-00235-6"},{"key":"e_1_3_4_7_2","volume-title":"FDA ODAC Votes Against the Applicability of STARGLO Data for Glofitamab Plus Chemo for U.S. Patients With R\/R DLBCL","author":"Ryan C","year":"2025","unstructured":"Ryan C: FDA ODAC Votes Against the Applicability of STARGLO Data for Glofitamab Plus Chemo for U.S. Patients With R\/R DLBCL. OncLive, 2025. https:\/\/www.onclive.com\/view\/fda-odac-votes-against-the-applicability-of-starglo-data-for-glofitamab-plus-chemo-for-u-s-patients-with-r-r-dlbcl"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00071-7"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058489"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl557"},{"key":"e_1_3_4_11_2","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha A","year":"2015","unstructured":"Midha A, Dearden S, McCormack R: EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 5:2892-2911, 2015","journal-title":"Am J Cancer Res"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/v14050986"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-023-01512-z"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389200220666190827160212"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad340"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000001168"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100840"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2021.01.006"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/app15094985"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.4103\/0974-1208.97779"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0532-4"},{"key":"e_1_3_4_22_2","unstructured":"IQVIA: Global Trends in R&D 2024: Activity productivity and enablers 2024. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/global-trends-in-r-and-d-2024-activity-productivity-and-enablers"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/blr.2015.9999"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.01.010"},{"key":"e_1_3_4_25_2","first-page":"75","article-title":"Evolution of the clinical trial landscape in Asia Pacific","volume":"6","author":"Yathindranath S","year":"2014","unstructured":"Yathindranath S, Kureishi A, Singh S, et al: Evolution of the clinical trial landscape in Asia Pacific. Open Access J Clin Trials 6:75-84, 2014","journal-title":"Open Access J Clin Trials"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2021.09.009"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.32482"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-25-00285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T18:34:06Z","timestamp":1772562846000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-25-00285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1200\/GO-25-00285"],"URL":"https:\/\/doi.org\/10.1200\/go-25-00285","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-05-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500285"}}